You can buy Adadx at the lowest price in the online pharmacy Nextgen.ooo . Adagrasib is an orally administered small molecule KRAS inhibitor developed by Mirati Therapeutics. KRAS mutations are very common in cancer and account for approximately 85% of all RAS family mutations. However, the development of KRAS inhibitors has proven challenging due to their high affinity for guanosine triphosphate and guanosine diphosphate, and the lack of a clear binding pocket. Adagrasib targets KRASG12C, one of the most common KRAS mutations, at cysteine ​​12 residue and inhibits KRAS-dependent signaling. In a Phase I/IB clinical trial involving patients with advanced solid tumors harboring a KRASG12C mutation, adagrasib demonstrated antitumor activity. A phase II study from the same study showed that in patients with KRASG12C-mutated non-small cell lung cancer (NSCLC), adagrasib was effective without new safety signals.
 
In February 2022, the FDA accepted a new drug application (NDA) for adagrasib for the treatment of patients with previously treated KRASG12C-positive NSCLC. In December 2022, the FDA granted adagrasib accelerated approval for the treatment of locally advanced or metastatic KRASG12C-mutated NSCLC who have received at least one prior systemic therapy. Adagrasib joins sotorasib as the other KRASG12C inhibitor approved by the FDA.